Etanercept in psoriasis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 10, 2004, Pages 2139-2146

  Papp, Kim A ^a  

^a PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

Anti TNF; Etanercept; Psoriasis; TNF receptor fusion protein

Indexed keywords

ACETRETIN; ALEFACEPT; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; RETINOID DERIVATIVE; RETINOL; SALICYLIC ACID; TAZAROTENE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CORRELATION FUNCTION; DEMYELINATING DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HEALTH CARE NEED; HUMAN; HYPERTENSION; INFLAMMATION; INJECTION SITE; INJECTION SITE REACTION; JOINT DESTRUCTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; LONG TERM CARE; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PHOTOTHERAPY; POPULATION RESEARCH; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT PLANNING; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 6444222553     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.10.2139     Document Type: Article

References (51)

1. KOO J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. (1996) 14(3):485-496.
2. KRUEGER JG, KRANE JF, CARTER DM, GOTTLIEB AB: Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J. Investig. Dermatol. (1990) 94(Suppl. 6):135S-140S.
3. KRUEGER G, KOO J, LEBWOHL M et al.: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. (2001) 137 3):280-284.
4. RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB Jr, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. (1999) 41(3 Pt 1):401-407.
5. KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. (2002) 46(1):1-23.
6. MIZUTANI H, OHMOTO Y, MIZUTANI T, MURATA M, SHIMIZU M: Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J. Dermatol. Sci. (1997) 14(2):145-153.
7. LONTZ W, SIRSJO A, LIU W et al.: Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha. Free Radic. Biol. Med. (1995) 18(2):349-355.
8. HOHLER T KRUGER A, SCHNEIDER PM et al.: A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J. Investig. Dermatol. (1997) 109 4):562-565.
9. KALUZA W, REUSS E, GROSSMANN S et al.: Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J. Investig. Dermatol. (2000) 114(6):1180-1183.
10. BONIFATI C, CARDUCCI M, CORDIALI FP et al.: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin. Exp. Dermatol. (1994) 19(5):383-387.
11. ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. (1994) 96 1):146-151.
12. MUSSI A, BONIFATI C, CARDUCCI M et al.: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regulat. Homeostat. Agents (1997) 11(3):115-118.
13. NICKOLOFF BJ, KARABIN GD, BARKER JN et al.: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am. J. Pathol. (1991) 138 1):129-140.
14. BONIFATI C and AMEGLIO F: Cytokines in psoriasis. Int. J. Dermatol. (1999) 38(4):241-251.
15. TAKEMATSU H, OZAWA H, YOSHIMURA T et al.: Systemic TNF administration in psoriatic patients: a promising therapeutic modality for severe psoriasis. Br. J. Dermatol. (1991) 124(2 ):209-210.
16. OH CJ, DAS KM, GOTTLIEB AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. (2000) 42(5 Pt 1):829-830.
17. PAPP KA, GUENTHER L, BOYDEN B et al.: Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J. Am. Acad. Dermatol. (2003) 48(1):48-54.
18. CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357(9271):1842-1847.
19. KIRBY B, MARSLAND AM, CARMICHAEL AJ, GRIFFITHS CE: Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol. (2001) 26(1):27-29.
20. FINLAY AY and COLES EC: The effect of severe psoriasis on the quality of life of 369 patients. Br. J. Dermatol. (1995) 132 2):236-244.
21. MIHATSCH MJ, WOLFF K: Consensus conference on cyclosporin A for psoriasis February 1992. Br. J. Dermatol. (1992) 126 6):621-623.
22. HO VC, GRIFFITHS CE, BERTH-JONES J et al.: Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J. Am. Acad. Dermatol. (2001) 44(4):643-651.
23. STERN RS, LAIRD N, MELSKI J et al.: Cutaneous squamous-cell carcinoma in patients treated with PUVA. N. Engl. J. Med. (1984) 310(18):1156-1161.
24. ROENIGK HH Jr, AUERBACH R, MAIBACH HI, WEINSTEIN GD: Methotrexate in psoriasis: revised guidelines. J. Am. Acad. Dermatol. (1988) 19(1 Pt 1):145-156.
25. KRUEGER GG, PAPP KA, STOUGH DB et al.: A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. (2002) 47(6):821-833.
26. LANGLEY R, BAKER D, ROBERTS J: The safety of alefacept using a reduced schedule for monitoring T cells. J. Am. Acad. Dermatol. (2004) 50(Suppl. 3):P592.
27. GORDON KB, TYRING SK, HAMILTON TK et al.: Examining duration of response and rebound during treatment with efalizumab (anti-CD11a). Proceedings of the 61st Annual Meeting of the American Academy of Dermatology, San Francisco, California, USA. March 21-26 (2003):P594.
28. Raptiva® (efalizumab) prescribing information. Genentech (2004).
29. MOHLER KM, TORRANCE DS, SMITH CA et al.: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. (1993) 151(3):1548-1561.
30. ALLDRED A: Etanercept in rheumatoid arthritis. Expert Opin. Pharmacother. (2001) 2(7):1137-1148.
31. Enbrel® (etanercept) prescribing information. Amgen and Wyeth (2004).
32. NESTOROV IP, DEVRIES TP, ZITNIK RM: Comparative pharmacokinetics of etanercept in patients with psoriasis or rheumatoid arthritis. J. Am. Acad. Dermatol. (2004) 50(Suppl 3):P572.
33. MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356(9227):385-390.
34. GOTTLIEB AB, MATHESON RT, LOWE N et al.: A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. (2003) 139(12):1627-1632.
35. LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. (2003) 349(21):2014-2022.
36. ELEWSKI BE, BOH E, PAPP KA et al.: Efficacy and safety of etanercept in patients with psoriasis: results of a global Phase III study. J. Am. Acad. Dermatol. (2004) 50(Suppl. 3):P618.
37. KRUEGER GG, FELDMAN SR, CAMISA C et al.: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J. Am. Acad. Dermatol. (2000) 43(2 Pt 1):281-285.
38. AREND SM, BREEDVELD FC, VAN DISSEL JT: TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. (2003) 61(4):111-119.
39. LONG R, GARDAM M: Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ (2003) 168(9):1153-1156.
40. NO AUTHORS LISTED: Severe tuberculosis while on infliximab (cont'd). Prescrire Int. (2002) 11(59):87.
41. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. (2001) 345(15):1098-1104.
42. LIBEROPOULOS EN, DROSOS AA, ELISAF MS: Exacerbation of tuberculosis enteritis after treatment with infliximab. Am. J. Med. (2002) 113(7):615.
43. MELLEMKJAER L, LINET MS, GRIDLEY G et al.: Rheumatoid arthritis and cancer risk. Eur. J. Cancer (1996) 32A 10):1753-1757.
44. BAECKLUND E, EKBOM A, SPAREN P, FELTELIUS N, KLARESKOG L: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br. Med. J. (1998) 317 7152):180-181.
45. Remicade® (infliximab) prescribing information. Centocor (2004).
46. VAN OOSTEN BW, BARKHOF F, TRLTYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 47(6):1531-1534.
47. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 53(3):457-465.
48. SHAKOOR N, MICHALSKA M, HARRIS CA, BLOCK JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359(9306):579-580.
49. SWALE VJ, PERRETT CM, DENTON CP, BLACK CM, RUSTIN MH: Etanercept-induced systemic lupus erythematosus. Clin. Exp. Dermatol. (2003) 28(6):604-607.
50. FERRACCIOLI GF, ASSALONI R, PERIN A: Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet (2002) 360 9333):645.
51. MOHAN AK, COTE TR, BLOCK JA et al.: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin. Infect. Dis. (2004) 39(3):295-299.